Common Drug Review (CDR) introduces new application fee for submissions
The Canadian Agency for Drugs and Technologies in Health (CADTH) is introducing an industry application fee for submissions made by drug manufacturers to CDR effective September 1, 2014 (April 1, 2015 for drugs submitted to the pan-Canadian Oncology Drug Review). All submissions with a Health Canada Notice of Compliance (NOC) or NOC with conditions date of September 1, 2014 or later will be subject to the fee.
The application fees will help finance an increase in the number of drugs that CADTH reviews on an annual basis and will supplement existing federal, provincial, and territorial funding.
A full review of the application fees will be undertaken in 2016, and every three years thereafter. Further information regarding the process, and terms and conditions of the fee will be communicated by CADTH closer to the September 1, 2014 implementation date.
For more information regarding the new fees, please see the pCODR announcement.